Enlarged periventricular space and periventricular lesion extension on baseline brain MRI predicts poor neurological outcomes in cryptococcus meningoencephalitis

Woo-Jin Lee1,2, Young Jin Ryu3, Jangsup Moon1,2,4, Soon-Tae Lee1, Keun-Hwa Jung1, Kyung-II Park1,2,5, Manho Kim1,6, Sang Kun Lee1 & Kon Chu1,2

In Cryptococcus neoformans meningoencephalitis, brain MRI findings might reflect the phathomechanism of disease progression that is fungal accumulation in the peri-venular space and consequent invasion into the parenchyma. This study analyzed serial brain MRI findings of 76 patients with cryptococcus meningoencephalitis in association with the disease progression and outcomes. MRI parameters included the enlarged periventricular space (ePVS) score (range 0–8), periventricular lesion extension, cryptococcoma, and hydrocephalus. Clinical outcomes at 2-week, 10-week, and 6-month were evaluated using modified Rankin scale (mRS). At 6 months, 15 (19.7%) patients died and 34 (44.1%) had poor neurological outcomes (mRS scores > 2). At baseline, an ePVS score of ≥ 5 (Odds-ratio [OR]: 94.173, 95% confidence-interval [95%CI]: 7.507–1181.295, P < .001), periventricular lesion extension (OR: 51.965, 95%CI: 2.592–1041.673, P = .010), and presence of encephalitis feature (OR: 44.487, 95%CI: 1.689–1172.082, P = .023) were associated with 6-month poor outcomes. Presence of two or more risk factors among encephalitis feature, ePVS score ≥ 5, and periventricular lesion extension at baseline, was associated with 6-month poor outcomes (area under the curve [AUC]: 0.978, P < .001) and mortality (AUC: 0.836, P < .001). Disease progression was associated with interval development of cryptococcoma and hydrocephalus. Brain MRI findings might be useful in predicting outcomes and monitoring the progression of cryptococcus meningoencephalitis.

Cryptococcus neoformans meningoencephalitis is a serious central nervous system (CNS) complication in immunocompromised patients and is associated with a high mortality rate1–4. Although protocols including the administration of intravenous amphotericin B combined with fluconazole for acute induction treatment and fluconazole for consolidation and long-term maintenance have been established as standard regimen2–5, the clinical outcomes are considerably heterogeneous and a significant portion of patients with mild baseline severity neurologically deteriorate and end up with death or permanent sequelae1,6–8. Prognostic factors for poor outcomes include old age, higher antigen titer in the cerebrospinal fluid (CSF), larger ex vivo capsule size of the fungus, increased or decreased intracranial pressure (ICP), high peripheral white blood cell (WBC) count, low body weight, anemia, and features that constitute encephalitis such as reduced Glasgow coma scale (GCS) scores or presence of a seizure. However, as the main outcome parameters in those previous studies were mortality, antigen clearance from...
the cerebrospinal fluid, or crudely the cure of the disease, which do not account for the neurological outcomes\textsuperscript{1,8,9}. One study evaluated cognitive outcomes for the patients who survived from cryptococcus meningitis, but it did not measure the overall neurological outcome\textsuperscript{7}. Therefore, a marker that reflects the disease pathomechanism and estimates the risk of disease progression and poor neurological outcome is still lacking\textsuperscript{6,7}.

The major route of entry of Cryptococcus into the CNS might be the key to explain the mechanism of disease progression and subsequent poor outcomes. Leukocyte-bound or free Cryptococci can exit the small-sized vessels in the brain and are accumulated in the perivascular space of the CNS, especially the peri-venular space\textsuperscript{10}. Considering that the peri-venular space lacks pial membrane\textsuperscript{11}, it can be postulated that the degree of peri-venular flow stagnation caused by the accumulated Cryptococcus might determine the risk of Cryptococcus invasion into the brain parenchyma, manifesting as the progression of disease\textsuperscript{4,10}.

Enlarged perivascular space (ePVS) is a common brain magnetic resonance imaging (MRI) feature associated with Cryptococcus meningoencephalitis\textsuperscript{12,13}. Given that ePVS might reflect the perivascular CSF flow stagnation caused by Cryptococcus accumulation, its degree might predict the risk of disease progression and poor outcomes. Similarly, other MRI findings such as parenchymal cryptococcoma or hydrocephalus might be utilized to monitor the neurological deterioration due to disease progression\textsuperscript{2,14}.

In this study, we hypothesized that brain MRI findings might reflect the pathomechanism underlying disease progression and predict the outcomes of Cryptococcus meningoencephalitis, and analyzed the brain MRI findings, their serial changes, and its association with the disease progression and outcomes.

**Materials and methods**

**Study subjects.** This retrospective cohort study initially included all consecutive individuals admitted to the neurology department of the Seoul National University Hospital between January 2000 and December 2019 who were diagnosed with Cryptococcus meningoencephalitis. Among the initially included 117 individuals, the final study population was defined according to the following criteria: (1) underwent baseline brain MRI evaluation; (2) availability of clinical, treatment, laboratory, and long-term (> 6 months) neurological outcome data. According to the criteria, 33 patients without brain MRI evaluations and eight with inadequate data were sequentially excluded and the remaining 76 individuals were included in the study analysis. Diagnosis of Cryptococcus meningoencephalitis was based on the detection of the Cryptococcus antigen in CSF by latex agglutination or by lateral flow assay along with or without detecting Cryptococcus in CSF by culture or India ink assay\textsuperscript{2,14,15}. The design of this study was approved by the institutional review board of the Seoul National University Hospital (SNUH) and the study was performed in accordance with the SNUH IRB regulations and the International Conference on Harmonisation guideline for Good Clinical Practice. Informed consent was waived by the IRB, as this study did not intervene with the evaluation or treatment process of the patients, and the patients were anonymized during the study process.

**Clinical and laboratory evaluation.** Along with the demographic information, patients’ underlying immune status was reviewed and the causes of immunodeficiency were categorized as follows: Human Immunodeficiency Virus (HIV) infection, hematologic malignancy, solid organ cancer, post-transplant status, and long-term use of high-dose immune suppressants (for indications other than cancer treatment or post-transplantation immunosuppression)\textsuperscript{4,16}. At baseline, encephalitis feature was defined according to the 2013 Consensus Statement of the International Encephalitis Consortium diagnostic criteria as: (1) altered mental status lasting more than 24 h without an alternative cause and (2) 3 or more of the followings: documented fever (> 38.0 °C); seizures not fully attributable to a preexisting seizure disorder; new onset of focal neurologic findings; CSF WBC count ≥ 5/mm\textsuperscript{3}; and abnormal brain MRI findings suggestive of encephalitis\textsuperscript{17}. Baseline GCS score and modified Rankin Scale (mRS) score data were also obtained from the patients’ medical records\textsuperscript{1}. mRS is a widely used clinical scale for measuring the neurological function and the degree of disability in the daily activities after a stroke or other neurological diseases\textsuperscript{18}. mRS ranges from 0 to 6, and each score represents neurological status as follows: 0, no symptoms or disabilities; 1, no significant disability despite some symptoms, which is able to perform all daily activities; 2, slight disability, which is able to carry out own daily activities without assistance, but not all previous activities; 3, moderate disability, which requires some help, but is able to walk unassisted; 4, moderately severe disability, which is unable to carry out own basic daily activities without assistance and unable to walk unassisted; 5, severe disability with bedridden status, which requires constant nursing care and attention; and 6, dead\textsuperscript{18}. Nowadays, mRS is also widely used in measuring outcomes for encephalitis\textsuperscript{19–23}.

CSF analysis included the evaluation of protein levels, WBC counts, and the elevation in the opening pressure (≥ 20 cmH\textsubscript{2}O)\textsuperscript{8}. CSF Cryptococcus antigen titer was evaluated semi-quantitatively, and high antigen titer was defined as antigen detection in > 1:1 000 dilution\textsuperscript{1}.

**Treatment profile analysis.** Intravenous amphotericin (0.7–1.0 mg/kg/day) with or without flucytosine (100 mg/kg/day) or fluconazole (400–800 mg/kg/day) was used for the induction treatment period (within 2 weeks from the treatment initiation). Oral fluconazole was used during the consolidation (8 weeks after the induction treatment) and long-term maintenance treatment period in most patients (74/76, 97.4%)\textsuperscript{5–6}. Treatment profiles with the durations of each treatment regimen were reviewed.

**Outcome analysis.** The scores on mRS was obtained at the time of treatment initiation, at 2 weeks, 10 weeks, and at 6 months. As a primary outcome, a mRS score of > 2 was designated as 6-month poor neurological outcome, according to the previous studies investigated the neurological outcomes in encephalitis\textsuperscript{19–23}. Serial follow-up CSF data at 2 weeks (window time of ± 3 days), at 10 weeks (window time of ± 1 week), and at 6 months
(window time of ± 1 month) were obtained if available. Antigen clearance was defined as negative conversion of
CSF Cryptococcus antigen evaluated at 2 weeks and at 10 weeks.

**Magnetic resonance imaging analysis.** Baseline and follow-up MRI were performed using 1.5-T or 3.0-T units with the protocols including T1/T2-weighted images and fluid-attenuated inversion recovery (FLAIR) sequences. Baseline and follow-up images were obtained from the same scanner. T1/T2-weighted images and FLAIR were obtained with the parameters as follows: slice number = 24–30, slice thickness/gap = 4.0–5.0/0.0–2.0 mm, repetition time/echo time = 6000–10,002/92–168.5 ms, field-of-view = 285–220 × 285–220 mm, and matrix = 220–512 × 192–400 (Supplemental Table 1 for the detailed MRI machines and parameters).

All the image analysis was separately performed by a neurologist (W.-J.L., 9 years of experience) and a radiologist (Y.R., 9 years of experience), blinded to all clinical data. Consensus was made by discussion for the discrepant cases. ePVS was defined as small, sharply delineated ovoid or linear lesions with T2-hyperintensity and T1-hypointensity. ePVS was semi-quantitatively rated in two brain regions—basal ganglia (BG) and centrum semiovale (CS)—using the scale introduced by Wardlaw et al., ranging 0–4 (0 for no, 1 for 1–10, 2 for 11–20, 3 for 21–40, and 4 for > 40 ePVS). BG- and the CS-ePVS scores were summed up to a total ePVS score ranging 0–824.

Periventricular lesion extension was defined as T2/FLAIR hyperintensity along the lateral ventricular border extending to the periventricular or subcortical parenchyma. Cryptococcoma was defined as single or multiple discrete T2/FLAIR hyperintensity lesions with T1 hypointensity in brain parenchyma. Hydrocephalus was defined as the Evans' index (the ratio of the maximal frontal horn width of lateral ventricle to the transverse inner skull diameter) of ≥ 0.3 (Fig. 1). For the 59 (77.6%) baseline MRIs with available T1 contrast enhancement images, the presence of an evident pathologic contrast enhancement in the brain parenchyma was also evaluated. To evaluate the serial changes in the MRI parameters, follow-up MRIs at 2 weeks (window time of ± 3 days), at 10 weeks (window time of ± 2 weeks), and at 6 months (window time of 5–10 months) were analyzed, if available.

**Statistical analysis.** SPSS 25.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Data were reported as numbers (percentages), means ± standard deviations, or medians [interquartile ranges, IQR]. In univariate analyses, Pearson’s chi-square test and Student’s t-test were used. To evaluate factors associated with a poor neurological outcome, logistic regression analyses were performed including the parameters with a P < .10 in univariate analyses using a backward elimination method. Age was included in the final model of every regression analysis. Regression analyses were also performed separately for the subgroup without an encephalitis feature at baseline. Regression analysis for mortality was not performed due to its low frequency. Receiver operating characteristic (ROC) curve were drawn to evaluate the prognostic value of the factors derived from the regression analysis and to designate a cut-off value for predicting a poor outcome. For every analysis, a P value < .05 was considered statistically significant. Inter-reader reliability for the MRI parameters were evaluated using Cohen's k values.
Results
Among the 76 patients (28 [36.8%] women, 48 [63.2%] men, mean age 55.4 ± 14.9 years [range, 19–80 years]), 51 (67.1%) patients were immune compromised and 25 (32.9%) were immune competent. At baseline, 22 (28.9%) patients presented with encephalitis. In baseline MRI, median BG-, CS-, and total ePVS scores were 2 [1–3], 2 [0–3], and 4 [1–6], respectively. Periventricular lesion extension was found in 41 (53.9%), cryptococcoma in 12 (15.8%), and hydrocephalus in 10 (13.2%) patients. Evident pathologic contrast enhancement in the brain parenchyma was found in 3 (5.1%) of the 59 patients with available T1 contrast enhancement images. Due to the significant portion of patients without baseline T1 contrast enhancement images and the low frequency of evident pathologic contrast enhancement in the brain parenchyma, this parameter was excluded from further outcome analysis. Inter-rater reliability was 0.97 (95% CI: 0.95–1.00) for a baseline ePVS score of ≥ 5, 0.95 (95% CI: 0.92–0.98) for a periventricular lesion extension, 0.96 (95% CI: 0.93–0.99) for a cryptococcoma, and 0.99 (95% CI: 0.95–1.00) for a hydrocephalus. The median time to treatment initiation was 3 [2–7] days from the onset of symptoms. For induction treatment, amphotericin was used in 76 (100.0%), flucytosine in 43 (56.6%), and fluconazole in 23 (30.3%) patients. For consolidation and maintenance, fluconazole was used in 74 (97.4%) patients. Amphotericin was maintained for 30 [20.3–42], flucytosine for 19 [10.5–31.5], and fluconazole for 110 [60–223] days.

The cumulative number of patients who achieved CSF antigen clearance at 10 weeks was 50 (65.8%). At 6 months, median mRS score was 2 [0–4] and mortality rate was 15 (19.7%). Detailed clinical, CSF, baseline MRI, treatment, and outcome profiles are described in Table 1. Numbers of patients with magnetic resonance image (MRI) evaluations included at each time points were 76, 40, 49, and 59 at baseline, 2-week, 10-week, and 6-months, respectively.

In the univariate analysis, poor 6-month outcome was associated with baseline encephalitis feature (P < .001), elevated CSF opening pressure (P < .001), the presence of periventricular extension (P = .001), cryptococcoma (P = .022), hydrocephalus (P < .001), and higher scores of GB-, CS-, and total ePVS (all P < .001) in the baseline MRI. Demographics, underlying immune status, treatment profiles were comparable between the groups with poor or good outcomes (Table 1). Subsequently, logistic regression analysis indicated that total ePVS score (Odds ratio [OR]: 5.068, 95% CI: 1.627–15.785 for 1 score increment, P = .005) was independently associated with a poor 6-month outcome. The association of the periventricular lesion extension was marginal (P = .056). When total ePVS score was dichotomized, an ePVS score of ≥ 5 (OR: 94.173, 95% CI: 7.507–1181.295, P < .001), baseline encephalitis feature (OR: 44.487, 95% CI: 1.689–1172.082, P = .023), and periventricular lesion extension (OR: 51.965, 95% CI: 2.592–1041.673, P = .010) were all independently associated with a poor 6-month outcome (Table 2).

In the univariate analysis for the factors associated with 6-month mortality, the mortality of 6-month was associated with baseline encephalitis feature (P = .013), elevated CSF opening pressure (P = .032), periventricular lesion extension (P < .001), cryptococcoma (P = .013), and higher scores of GB-, CS-, and total ePVS (all P < .001) in the baseline MRI (Table 3). Due to low frequency (n = 15), multivariate analysis for mortality was not performed.

We compared the clinical profiles and the outcomes between the groups with or without baseline encephalitis feature. The group with baseline encephalitis feature was associated with a higher frequency of HIV infection (P = .015), GCS score < 15 (P < .001), elevated CSF opening pressure (P < .001), the presence of periventricular extension (P < .001), cryptococcoma (P = .015), and hydrocephalus (P = .021) in the baseline MRI, and lower baseline mRS scores and higher scores of GB-, CS-, and total ePVS, compared to the group without encephalitis feature (all P < .001). The 6-month mRS score was also lower in the subgroup with baseline encephalitis feature (P < .001, Supplemental Table 2).

In the regression analysis to evaluate the factors associated with poor 6-month outcomes in the subpopulation without baseline encephalitis feature, total ePVS score (OR: 4.331, 95% CI: 1.457–12.875 for 1 score increment, P = .008) was associated with a poor 6-month outcome. In the model with dichotomized ePVS value, ePVS score ≥ 5 (OR: 60.073, 95% CI: 5.152–700.485, P < .001) and periventricular lesion extension (OR: 23.106, 95% CI: 2.796–297.176, P = .016) were significantly associated with a poor 6-month outcome (Supplemental Table 3).

Risk score for a poor 6-month outcome was calculated by summing up the number of the factors associated with poor outcomes (encephalitis feature, ePVS score ≥ 5, and periventricular lesion extension), with a score range of 0–3. In ROC curve analysis for the total study population, the risk score predicted a poor 6-month outcome with area under the curve (AUC) of 0.978 (95% CI: 0.950–1.000, P < .001) and 6-month mortality with AUC of 0.836 (95% CI: 0.745–0.927, P < .001, Fig. 2A and B). The risk score of 2 predicted a poor 6-month outcome with a sensitivity of 94.1% and a specificity of 95.2%, and 6-month mortality with a sensitivity of 93.3% and a specificity of 67.2%. For the subgroup without baseline encephalitis feature, the risk score predicted a poor 6-month outcome with AUC of 0.952 (95% CI: 0.896–1.000, P < .001) and 6-month mortality with AUC of 0.870 (95% CI: 0.764–0.978, P = .003, Fig. 2C and D). In this subgroup, the risk score of 2 predicted a poor 6-month outcome with a sensitivity of 85.7% and a specificity of 95.0%, and 6-month mortality with a sensitivity of 83.3% and a specificity of 81.2%.

Two-week follow-up MRI evaluation data were available for 40 (59.7%), 10-week follow-up MRI for 49 (64.5%), and 6-month follow-up MRI for 59 (77.6%) patients. The median number of MRI evaluations analyzed per patient was 3 [3–3]. When the serial changes in the MRI parameters were analyzed in association with the changes in mRS scores, the subgroup with baseline ePVS score ≥ 5 showed gradual deterioration in the mRS score along with progressive increment of the frequency of cryptococcoma and hydrocephalus (Fig. 3A), whereas the subgroup with baseline ePVS score < 5 showed gradual improvement in the mRS score and maintained a low frequency of periventricular lesion extension, cryptococcoma, and hydrocephalus in the follow-up MRIs (Fig. 3B). A similar trend was observed in the subgroup without baseline encephalitis feature (Fig. 3C and D, see
**Fig. 4 for representative cases).** The profiles of the MRI parameters between the groups evaluated using 1.5-T or 3.0-T MRI machines were comparable (Supplemental Table 4).

**Discussion**

This study demonstrated clinical and MRI parameters associated with the progression and the poor outcomes of Cryptococcus meningoencephalitis. Along with the baseline encephalitis feature, a high ePVS score and periventricular lesion extension were independently associated with poor outcomes. Especially, presence of two or more risk factors at baseline showed high association with poor neurological outcomes and mortality, indicating that these might serve as prognostic markers. Given that the association was still valid for the subgroups without baseline encephalitis feature, these prognostic factors not only reflect the disease severity but also predict the

**Table 1.** Comparison of the clinical, laboratory, and treatment profiles between the groups with or without poor outcomes. Data are reported as mean ± standard deviation, or as median [interquartile range, IQR]. *HIV* human immunodeficiency virus, *GCS* Glasgow coma scale, *mRS* modified Rankin scale, *CSF* cerebrospinal fluid, *WBC* white blood cell, *ePVS* enlarged perivascular space. *P* < .05 and **P** < .01.

| Demographic and clinical profiles | Total (n = 76) | Good 6-month outcome (n = 42) | Poor 6-month outcome (n = 34) | P |
|-----------------------------------|---------------|-------------------------------|------------------------------|---|
| Female sex (%)                    | 28 (36.8)     | 14 (33.3)                     | 14 (41.2)                    | .387 |
| Age of onset (years)              | 55.4 ± 14.9   | 52.9 ± 16.6                   | 58.6 ± 12.2                  | .117 |
| Underlying immune status          |               |                               |                              |    |
| Compromised                       | 51 (67.1)     | 31 (73.8)                     | 20 (58.8)                    | .324 |
| HIV infection                     | 19 (25.0)     | 11 (26.2)                     | 8 (23.5)                     | .895 |
| Hematologic malignancy            | 12 (15.8)     | 9 (21.4)                      | 3 (8.8)                      | .165 |
| Solid organ cancer                | 9 (11.8)      | 5 (11.9)                      | 4 (11.8)                     | .948 |
| Post-transplant                   | 4 (5.3)       | 2 (4.8)                       | 2 (5.9)                      | .788 |
| High-dose immune suppressant      | 7 (9.2)       | 4 (9.5)                       | 3 (8.8)                      | .975 |
| Immune competent                  | 25 (32.9)     | 11 (26.2)                     | 14 (41.2)                    | .324 |
| Fever > 38.0 °C                   | 70 (92.1)     | 40 (95.2)                     | 30 (88.2)                    | .264 |
| GCS < 15                          | 40 (52.6)     | 18 (42.9)                     | 22 (64.7)                    | .095 |
| Seizure                           | 7 (9.2)       | 2 (4.8)                       | 5 (14.7)                     | .147 |
| Encephalitis                      | 22 (28.9)     | 2 (4.8)                       | 20 (58.8)                    | < .001** |
| mRS score                         | 2 [1–3]       | 1 [1–2]                       | 3 [2–4]                      | < .001** |
| CSF profiles                       |               |                               |                              |    |
| CSF protein level (mg/dL)         | 75 [59–118]   | 69 [56–80.6]                  | 84 [67.5–202.5]              | .079 |
| CSF WBC count (/µL)               | 46.5 [8.3–137.3] | 68 [8–164.8]                  | 38 [11–82.5]                 | .482 |
| CSF opening pressure (≥ 20 cm H2O) | 32 [42.1]  | 10 (23.8)                     | 22 (64.7)                    | < .001** |
| High Ag titer (> 1000)            | 2 (2.6)       | 0 (0.0)                       | 2 (5.9)                      | .160 |
| MRI profiles                       |               |                               |                              |    |
| BG ePVS score                     | 2 [1–3]       | 1 [0–2]                       | 3 [2–3]                      | < .001** |
| CS ePVS score                     | 2 [0–3]       | 0 [0–2]                       | 3 [3–4]                      | < .001** |
| Total ePVS score                  | 4 [1–6]       | 1 [0–3]                       | 6 [5–7]                      | < .001** |
| Periventricular lesion extension   | 41 (53.9)     | 10 (23.8)                     | 31 (91.2)                    | < .001** |
| Cryptococcoma                     | 12 (15.8)     | 1 (2.4)                       | 11 (32.4)                    | .01** |
| Hydrocephalus                      | 10 (13.2)     | 1 (2.4)                       | 9 (26.5)                     | .22** |
| Treatment profiles                |               |                               |                              |    |
| Induction treatment               |               |                               |                              |    |
| Amphotericin                      | 76 (100.0)    | 42 (100.0)                    | 34 (100.0)                   | 1.000 |
| Flucytosine                       | 43 (56.6)     | 23 (54.8)                     | 20 (58.8)                    | .541 |
| Fluconazole                       | 23 (30.3)     | 14 (33.3)                     | 9 (26.5)                     | .317 |
| Fluconazole consolidation + mainte- | 74 (97.4)  | 40 (95.2)                     | 34 (100.0)                   | .425 |
| nance treatment                   |               |                               |                              |    |
| Outcome profiles                  |               |                               |                              |    |
| Antigen clearance at 2-weeks      | 28 (36.8)     | 25 (59.5)                     | 3 (8.8)                      | < .001** |
| Antigen clearance at 10-weeks     | 50 (65.8)     | 37 (88.1)                     | 13 (38.2)                    | < .001** |
| mRS score at 10-weeks             | 2 [0–4]       | 0 [0–1]                       | 5 [4–6]                      | < .001** |
| Mortality at 10-weeks             | 10 (13.2)     | 0 (0.0)                       | 10 (29.4)                    | .004** |
| mRS score at 6-months             | 2 [0–4]       | 0 [0–0]                       | 5 [4–6]                      | < .001** |
| Mortality at 6-months             | 15 (19.7)     | 0 (0.0)                       | 15 (44.1)                    | < .001** |
### Table 2. Logistic regression models for poor 6-month outcomes. *P<.05 and **P<.01.

| Model 1 | Odd ratio (95% CI) | P     | R²  |
|---------|-------------------|-------|-----|
| Model 2 |                    |       |     |

| Variable                  | Odd ratio (95% CI) | P     |
|---------------------------|--------------------|-------|
| Age (years)               | 0.951 (0.854–1.059) | .358  |
| Encephalitis              | 47.271 (0.221–10,111.603) | .159  |
| ePVS score                | 5.068 (1.627–15,785) | .005** |
| Periventricular extension | 13.093 (0.924–185,574) | .057  |

| Variable                  | Odd ratio (95% CI) | P     |
|---------------------------|--------------------|-------|
| Age (years)               | 0.968 (0.876–1.070) | .524  |
| Encephalitis              | 44.487 (1.689–1172.082) | .023* |
| ePVS score ≥ 5            | 94.173 (7.507–1181.295) | <.001** |
| Periventricular extension | 51.965 (2.592–1041.673) | .010* |

### Table 3. Univariate analysis for the factors associated with 6-month mortality. Data are reported as mean ± standard deviation, or as median [interquartile range, IQR]. HIV human immunodeficiency virus, GCS Glasgow coma scale, mRS modified Rankin scale, CSF cerebrospinal fluid, WBC white blood cell, ePVS enlarged perivascular space. *P<.05 and **P<.01.

| Demographic and clinical profiles | 6-month survivor (n = 42) | 6-month non-survivor (n = 15) | P     |
|----------------------------------|---------------------------|-------------------------------|-------|
| Female sex (%)                   | 22 (36.1)                 | 6 (40.0)                      | .781  |
| Age of onset (years)             | 55.2 ± 15.9               | 56.4 ± 10.4                   | .717  |
| Underlying immune status         |                           |                               |       |
| Compromised                      | 41 (67.2)                 | 11 (73.3)                     | .653  |
| HIV infection                    | 17 (27.9)                 | 2 (13.3)                      | .189  |
| Hematologic malignancy           | 11 (18)                   | 1 (6.7)                       | .181  |
| Solid organ cancer               | 3 (4.9)                   | 4 (26.7)                      | .153  |
| Post-transplant                   | 5 (8.2)                   | 1 (6.7)                       | .789  |
| High-dose immune suppressant     | 6 (9.8)                   | 1 (6.7)                       | .708  |
| Immune competent                 | 20 (32.8)                 | 4 (26.7)                      | .653  |
| Fever > 38.0 °C                  | 57 (93.4)                 | 13 (86.7)                     | .390  |
| GCS < 15                         | 30 (49.2)                 | 10 (66.7)                     | .230  |
| Seizure                          | 5 (8.2)                   | 2 (13.3)                      | .544  |
| mRS score ≥ 3                    | 13 (21.3)                 | 9 (60)                        | .013* |
| CSF protein level (mg/dL)        | 73.5 [59.3–97.9]          | 100 [50–196]                  | .810  |
| CSF WBC count (/µL)              | 58 [12–144]               | 21 [0–135]                    | .402  |
| CSF opening pressure (≥ 20 cm H₂O) | 22 (36.1)               | 10 (66.7)                     | .032* |
| High Ag titer (> 1000)           | 1 (1.6)                   | 1 (6.7)                       | .476  |
| MRI profiles                     |                           |                               |       |
| BG ePVS score                    | 2 [0–2]                   | 3 [3–3]                       | <.001** |
| CS ePVS score                    | 2 [0–3]                   | 3 [3–4]                       | <.001** |
| Total ePVS score                 | 3 [0–5]                   | 6 [5–7]                       | <.001** |
| Periventricular lesion extension | 27 (44.3)                 | 14 (93.3)                     | <.001** |
| Cryptococcoma                    | 5 (8.2)                   | 7 (46.7)                      | .013* |
| Hydrocephalus                    | 6 (9.8)                   | 4 (26.7)                      | .193  |
| Treatment profiles               |                           |                               | .769  |
| Induction treatment              |                           |                               |       |
| Amphotericin                     | 42 (100.0)                | 15 (100.0)                    | 1.000 |
| Flucytosine                      | 34 (55.7)                 | 9 (60.0)                      | .769  |
| Fluconazole                      | 17 (27.9)                 | 6 (40.0)                      | .558  |
| Fluconazole consolidation + maint | 59 (96.7)                 | 15 (100.0)                    | .484  |
risk of progression. Additionally, neurological deterioration manifested in brain MRI data as development of cryptococcoma and progression of hydrocephalus, which suggests that these MRI markers can also be used for monitoring the progression of disease.

According to a large-sized prospective study of 501 patients with HIV infection, high fungal burden in the CSF, altered mental status, old age, high peripheral WBC count, low body weight, anemia, and low CSF opening pressure were associated with 10-week mortality. Further, combination treatment of amphotericin and flucytosine at induction period reduced 10-week mortality while fluconazole-based induction treatment was associated with higher mortality. However, these studies mainly focused on mortality or fungal clearance in the CSF, while the neurological outcome of Cryptococcus meningoencephalitis has not been investigated in depth. In this regard, this is the first study to describe the dynamic neurologic course of the disease, and demonstrate the early accessible MRI factors that are useful to predict or monitor the neurological outcomes.

Notably, the outcome predictors in the current study reflect the distinct pathomechanism underlying the progression of Cryptococcus meningoencephalitis and can therefore be related with the previously reported prognostic factors for mortality. High fungal antigen titer and larger fungus capsule size might also contribute to a mechanical stagnation of CSF flow, especially in the peri-venular space which has small diameter. Therefore, these factors can be correlated with the enlarged PVS in the baseline MRI which reflects the degree of CSF stasis.
Altered mental status is a factor constituting a baseline encephalitis feature and is also related to MRI indicators of the parenchymal invasion of the Cryptococcus, such as periventricular lesion extension and cryptococcoma. Increased ICP might also be the consequence of CSF recirculation failure resulting from the wide-spread cryptococcus accumulation over the perivascular space and manifest as the progression of hydrocephalus in MRI. In addition to outcome prediction and disease monitoring, the findings of the current study can also be useful for risk estimation and deciding the treatment strategy. For the patients with ≥ 2 baseline risk factors, higher combination or higher dose of anti-fungal treatment could be used to prevent the patient deterioration. Additionally, frequent follow-up brain imaging to monitor the progression might be beneficial for the timely detection and early intervention to lower the ICP or other neurological complications.

Figure 3: Serial changes in the MRI parameters and the modified Rankin scale (mRS) scores. Panel (A) demonstrates the subgroup with baseline ePVS score ≥ 5 (n = 37) and Panel (B) describes the subgroup with baseline ePVS score < 5 (n = 39) in the whole study population (n = 76). Panel (C) demonstrates the subgroup with baseline ePVS score ≥ 5 (n = 18) and Panel (D) describes the subgroup with baseline ePVS score < 5 (n = 36) in the subgroup without baseline encephalitis feature (n = 54). The bar graph indicates the modified Rankin scale (mRS) score profiles and the line graphs indicates the changes in the frequency of each MRI findings and the changes in the total enlarged perivascular space (ePVS) score. The numbers in the X axis indicates the number of patients included in the MRI analysis in each time point. Every patient was included in each time point of the mRS graph.

Altered mental status is a factor constituting a baseline encephalitis feature and is also related to MRI indicators of the parenchymal invasion of the Cryptococcus, such as periventricular lesion extension and cryptococcoma. Increased ICP might also be the consequence of CSF recirculation failure resulting from the wide-spread cryptococcus accumulation over the perivascular space and manifest as the progression of hydrocephalus in MRI.
Figure 4. Illustrative cases. A 56-year-old man with underlying human immunodeficiency virus infection presented with fever and headache (initial modified Rankin Scale [mRS] score = 1). Baseline MRI showed enlarged periventricular space (EPVS) in centrum semiovale (CS-EPVS score = 4) and in basal ganglia (BG-EPVS score = 2, Panel (A)). The patient was treated with intravenous amphotericin combined with fluconazole for two weeks. However, follow-up MRI at 2 week showed interval development of parenchymal T2 high-signal intensity (HSI) at the right frontal cortex on T2 fluid attenuated inversion recovery (FLAIR) images (Panels (B)). Despite the amphotericin-based combination treatment for 40 days and oral fluconazole for 176 days, the mRS score at 6 month was 4. A 72-year-old immunocompetent woman presented with fever and headache (initial mRS score = 1). At baseline MRI, CS-EPVS score was 3 and BG-EPVS score was 2 (Panels (C)). The patient was treated with intravenous amphotericin combined with flucytosine and maintained with oral fluconazole for 214 days. However, gait disturbance and cognitive impairment progressed (6-month mRS score = 4). Follow-up MRI at 6 month showed interval development of periventricular extension of the T2 HSI and slight hydrocephalus on T2 FLAIR images (Evans ratio = 0.35, Panels (D)).
The current study has several limitations. First, as a retrospective study, the number and the interval of CSF and MRI evaluations, and treatment regimen were heterogeneous and not standardized. Second, the study population with baseline MRI evaluation might bear a potential source of selection bias, as this criteria might exclude patients with severe or unstable baseline clinical status. Different subpopulations included in each time point of the serial MRI data analysis also warrant a careful interpretation of the result. Third, this study included both 1.5-T and 3.0-T machines, although baseline and follow-up images were obtained from the same scanner and the MRI parameter profiles between the groups with different MRI powers were comparable. Fourth, the rate of fungal clearance in CSF, one of the major parameters for determining treatment outcome, was not analyzed in this study24. Fifth, although the presence of pathological parenchyma contrast enhancement might be a potential outcome predictor as it represents a significant breakdown of blood–brain barrier, it was excluded from the outcome analysis due to the low frequency and the significant portion of patients without baseline T1 contrast enhancement images. Additionally, careful discrimination of PVs and periventricular lesion extension from aging-related cerebral small-vessel disease is warranted, although their associations with outcomes were significant after adjusting for age.

**Ethics approval.** The design of this study was approved by the institutional review board of the Seoul National University Hospital.

**Data availability**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 3 December 2020; Accepted: 8 March 2021
Published online: 19 March 2021

**References**

1. Jarvis, J. N. et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. *Clin. Infect. Dis.* **58**, 736–745 (2014).
2. Perfect, J. R. & Bicanic, T. Cryptococcosis diagnosis and treatment: what do we know now. *Fungal Genet. Biol.* **78**, 49–54 (2015).
3. Day, J. N. et al. Combination antifungal therapy for cryptococcal meningitis. *N. Engl. J. Med.* **368**, 1291–1302 (2013).
4. Williamson, P. R. et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. *Nat. Rev. Neurol.* **13**, 13 (2017).
5. Brouwer, A. E. et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. *Lancet* **363**, 1764–1767 (2004).
6. Mitchell, D. H. et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. *Clin. Infect. Dis.* **20**, 611–616 (1995).
7. Carlson, R. D. et al. Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. *Metab. Brain Dis.* **29**, 269–279 (2014).
8. Bicanic, T. et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. *AIDS* **23**, 701–706 (2009).
9. Robertson, E. J. et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. *J. Infect. Dis.* **209**, 74–82 (2014).
10. Kaufman-Francis, K. et al. The early innate immune response to, and phagocyte-dependent entry of, *Cryptococcus neoformans* map to the perivascular space of cortical post-capillary venules in neurocryptococcosis. *Am. J. Pathol.* **188**, 1653–1665 (2018).
11. Bechmann, L., Galea, I. & Perry, V. H. What is the blood–brain barrier (not)? *Trends Immunol.* **28**, 5–11 (2007).
12. Corti, M., Villafane, M. E., Negroni, R., Arechavala, A. & Maioło, E. Magnetic resonance imaging findings in AIDS patients with central nervous system cryptococcosis. *Rev. Iberoam. Microl.* **25**, 211 (2008).
13. Charlier, C. et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. *PLoS ONE* 3, e1950 (2008).
14. Nalintya, E., Kiggundu, R. & Meya, D. Evolution of cryptococcal antigen testing: what is new? *Curr. Fungal Infect. Rep.* **10**, 62–67 (2016).
15. Rajasingham, R. et al. Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing. *J. Clin. Microbiol.* https://doi.org/10.1128/JCM.01238-18 (2019).
16. Kontoyiannis, D. P. et al. Cryptococcosis in patients with cancer. *Clin. Infect. Dis.* **32**, e145–e150 (2001).
17. Venkatesan, A. et al. Case definitions, diagnostic algorithms, and priorities in encephalitis consensus statement of the international encephalitis consortium. *Clin. Infect. Dis.* **57**, 1114–1128 (2013).
18. Quinn, T. J., Dawson, J., Walters, M. & Lees, K. R. Reliability of the modified Rankin Scale: a systematic review. *Stroke* **40**, 3393–3395 (2009).
19. Lee, W.-J. et al. Teratoma removal, steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in anti-NMDAR encephalitis. *Neurotherapeutics* https://doi.org/10.1007/s13311-020-00921-7 (2020).
20. Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol.* **12**, 157–165 (2013).
21. Lee, W.-J. et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. *Neurotherapeutics* **13**, 824–832 (2016).
22. Lee, W.-J. et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. *Neurology* https://doi.org/10.1212/WNL.0000000000002635 (2016).
23. Balu, R. et al. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. *Neurology* **92**, e244–e252 (2019).
24. Wardlaw, J. M. et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* **12**, 822–838 (2013).
25. Longley, N. et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. *Clin. Infect. Dis.* **47**, 1556–1561 (2008).
26. Mollov, S. F. et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. *N. Engl. J. Med.* **378**, 1004–1017 (2018).
27. Nussbaum, J. C. et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. *Clin. Infect. Dis.* **50**, 338–344 (2010).
28. Segal, B. H. et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47, 674–683 (2008).

**Author contributions**
W.J.L. contributed in study data acquisition, data analysis and interpretation, and drafting manuscript. Y.J.R. participated in MR image acquisition and analysis. J.S.M. contributed in conception and design of the study. S.T.L. contributed in patient management, and manuscript revision. K.H.J. participated in MR image management and analysis. K.I.P. participated in manuscript editing and production of figures and tables. M.K. participated in acquisition, analysis, and management of data. S.K.L. contributed in initial conceptualization and design of the study, patient management, manuscript revision, and supervision of the entire procedures in this study.

**Funding**
This study was funded by ILDONG PHARMACEUTICAL CO., LTD. (0620191880, Republic of Korea).

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-85998-6.

**Correspondence** and requests for materials should be addressed to K.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021, corrected publication 2021